Top Medical News
10 minutes ago
Variations in albuminuria predict changes in renal risk among patients with hypertension and type 2 diabetes (T2D) under real-life clinical conditions, reports a study, suggesting that albuminuria status may help optimize therapeutic strategy.
Adolescents who sleep longer and have higher sleep efficiency have a favourable cardiometabolic profile, including lower abdominal adiposity, lower systolic blood pressure and higher high-density lipoprotein cholesterol levels, as shown in a study.
Canakinumab provides effective flare control and prevention in patients with monogenic autoinflammatory diseases, namely colchicine-resistant familial Mediterranean fever, mevalonate kinase deficiency and tumour necrosis factor receptor–associated periodic syndrome, according to the results of a phase III CLUSTER trial.
Loss of control over eating (LOC) in pregnancy is common and has short- and long-term adverse effects on mother and offspring, according to a study, adding that pregnancy LOC merits further attention.
Stephen Padilla, Yesterday
Diabetic patients in a decompensated state and who develop type 2 myocardial infarction (MI) have an increased risk for mortality and major adverse cardiac events (MACE), according to a new study. In addition, these patients are potentially at risk for undiagnosed coronary artery disease.
2 days ago
Diets rich in polyphenols, particularly flavonoids, provide a protective effect against type 2 diabetes (T2D), according to a recent meta-analysis.
3 days ago
Switching from thiazide diuretic to ipragliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, leads to improvements in metabolic parameters and body mass composition without affecting blood pressure in type 2 diabetes (T2D) patients, a recent study has found.
Special Reports
31 May 2018
At the recent ‘Reinforced for the Glycaemic Challenge’ symposium held at Shangri-la Hotel, Kuala Lumpur, Associate Professor Dr Alexander Tan, Professor Dr Chee Kok Han and Dr Chan Siew Pheng shared their insights into the importance of achieving glycaemic control in patients with type 2 diabetes mellitus (T2DM), while simultaneously providing them with cardiovascular protection.
05 Apr 2017
At a recent lunch symposium held in conjunction with the 1st Malaysian Advances in Women’s Health Congress 2016, Professor Dr Jamiyah Hassan imparted clinical updates and strategies for the optimization of hormone replacement therapy in menopausal women. Highlights from her presentation are summarized below.
20 Jan 2017
At the recent Malaysian Osteoporosis Society 2016 Clinical Practice Guideline (CPG) Meeting held on the 8th of October 2016 at Ibis Styles Ipoh, Dr Hew Fen Lee and Professor Dr Chan Siew Pheng presented clinical guidance on the management of osteoporosis, and discussed whether the benefits of treatment outweigh the risks.
04 Jan 2017
At the Diabetes Asia 2016 Conference organized by the National Diabetes Institute, Professor Jean Claude Mbanya presented the case for why gliclazide modified release (MR; Diamicron® MR, Servier) should be the treatment of choice for early and aggressive control of type 2 diabetes (T2D).
16 Dec 2016
BASALOG – Insulin glargine (rDNA) 100 IU/mL soln for inj (cartridge) – CCM Pharmaceuticals
16 Dec 2016
INVOKANA – Canagliflozin hemihydrate 100 mg and 300 mg FC tab – Johnson & Johnson (Janssen)
Pearl Toh, 07 Dec 2016
Preventing hypertension, diabetes, and obesity, which are the major risk factors for heart failure (HF), by ages 45 and 55 years may lower risks of incident HF and prolong HF-free survival, suggests data from the Cardiovascular Disease Lifetime Risk Pooling Project.
Conference Reports
Pearl Toh, 10 Jul 2018
A dual-hormone artificial pancreas (DAP) with a rapid delivery of insulin and pramlintide in a fixed ratio improves glycaemic control and reduces glucose variability in adults with type 1 diabetes (T1D) compared with first-generation artificial pancreas delivering insulin alone, according to a study presented at ADA 2018.
Roshini Claire Anthony, 10 Jul 2018

Combining the dual sodium glucose cotransporter (SGLT) 1 and 2 inhibitor sotagliflozin with optimized insulin therapy led to sustained reductions in HbA1c levels over 1 year in adults with type 1 diabetes (T1D), according to a study presented at ADA 2018.

Elvira Manzano, 06 Jul 2018
Combined treatment with the GLP-1 receptor agonist exenatide and the SGLT-2 inhibitor dapagliflozin appeared to be effective up to 2 years in patients with type 2 diabetes (T2D), the phase III DURATION-8 extension trial has shown.
Elvira Manzano, 06 Jul 2018
The risk of autism may be higher in children of mothers with type 1 diabetes (T1D) than those without, suggests a retrospective cohort analysis.
Roshini Claire Anthony, 05 Jul 2018

The sodium glucose co-transporter 2 (SGLT-2) inhibitor canagliflozin does not appear to increase the risk of below-knee lower extremity amputations over other SGLT2 inhibitors or non-SGLT2 inhibitor antihyperglycaemic agents in patients with type 2 diabetes (T2D), but may reduce the risk of hospitalization for heart failure (HHF), according to findings of the US-based OBSERVE-4D* study.

Stephen Padilla, 05 Jul 2018
Intensified multipronged treatment in patients with type 2 diabetes (T2D) for 7.8 years is not associated with any significant increase in total costs or in costs per person-year when compared to conventional multipronged treatment over a follow-up of 21.2 years, according to the results of the Steno 2 Study presented at the 78th Scientific Sessions of the American Diabetes Association (ADA 2018).
Audrey Abella, 05 Jul 2018
The addition of the sodium-glucose cotransporter-2 inhibitor ertugliflozin to metformin improved glycaemic control, body weight, and blood pressure (BP) in patients with inadequately controlled type 2 diabetes (T2D), according to the results of the VERTIS MET* trial presented at ADA 2018.
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download